Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March 5, 2018
February 22 2018 - 8:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell
therapies for the sports medicine and severe burn care markets,
today announced the following webcast and conference call to
discuss its fourth-quarter and full-year 2017 financial results,
business highlights and 2018 financial guidance.
|
|
|
What: |
|
Vericel Corporation
Fourth-Quarter 2017 Earnings Call |
|
|
|
When: |
|
Monday, March 5, 2018
at 8:30am (EST) |
|
|
|
Where: |
|
http://investors.vcel.com/events-presentations |
|
|
|
How: |
|
The conference call
will be available live in the Investors section of the Vericel
website at http://investors.vcel.com/events-presentations.
Please access the site at least 15 minutes prior to the
scheduled start time in order to download the required audio
software if necessary. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation fourth-quarter 2017
earnings call. If calling from outside the U.S., please use the
international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at
http://investors.vcel.com/events-presentations until March 5,
2019. A replay of the call will also be available until 11:30am
(EST) on March 10, 2018 by calling (855) 859-2056, or from outside
the U.S. (404) 537-3406. The conference ID is 4899311.
About Vericel CorporationVericel is a leader in
advanced cell therapies for the sports medicine and severe burn
care markets. The company markets two cell therapy products in the
United States. Vericel is marketing MACI® (autologous cultured
chondrocytes on porcine collagen membrane), an autologous
cellularized scaffold product indicated for the repair of
symptomatic, single or multiple full-thickness cartilage defects of
the knee with or without bone involvement in adults. Vericel is
also marketing Epicel® (cultured epidermal autografts), a permanent
skin replacement for the treatment of patients with deep dermal or
full thickness burns greater than or equal to 30% of total body
surface area. For more information, please visit the company's
website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. © 2018 Vericel Corporation. All rights reserved.
Global Media Contacts:David SchullRusso
Partners LLC+1 212-845-4271 (office)+1 858-717-2310
(mobile)David.schull@russopartnersllc.com
Karen ChaseRusso Partners LLC+1 646-942-5627 (office)+1
917-547-0434 (mobile)Karen.chase@russopartnersllc.com
Investor Contacts: Chad RubinThe Trout
Groupcrubin@troutgroup.com+1 (646) 378-2947
Lee SternThe Trout Grouplstern@troutgroup.com+1 (646)
378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024